Related Experiment Video

Updated: Aug 7, 2026

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Molecular targeting therapy for renal cell carcinoma

Masatoshi Eto1, Seiji Naito

  • 1Department of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. etom@uro.med.kyushu-u.ac.jp

International Journal of Clinical Oncology
|July 20, 2006
PubMed

Insights

New targeted therapies show promise for metastatic renal cell carcinoma (RCC), a difficult-to-treat cancer. Vascular Endothelial Growth Factor Receptor (VEGFR) pathway inhibitors are demonstrating significant clinical activity in advanced RCC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Metastatic renal cell carcinoma (RCC) presents significant treatment challenges due to its resistance to conventional therapies.
  • Recent advancements in understanding RCC molecular pathways have paved the way for novel therapeutic strategies.

Purpose of the Study:

  • To review the development and clinical application of targeted therapies for metastatic RCC.
  • To highlight the role of vascular endothelial growth factor receptor (VEGFR) pathway inhibition in treating advanced RCC.

Main Methods:

  • Review of recent clinical trials and FDA-approved agents targeting VEGFR and related kinases.
  • Analysis of the molecular mechanisms targeted by new RCC therapies.

Main Results:

  • Two multi-kinase inhibitors (BAY 43-9006 and SU 11248) targeting VEGFR, PDGFR, FLT3, KIT, and Raf kinase are FDA-approved for advanced RCC.
  • Ongoing Phase III trials are evaluating VEGF inhibition combined with interferon alpha (IFN-alpha).
  • VEGF inhibition has shown promising clinical responses in historically resistant RCC.

Conclusions:

  • VEGF pathway inhibition represents a significant breakthrough in the treatment of advanced metastatic renal cell carcinoma.
  • Ongoing research and clinical trials are crucial to further define the role of these novel agents in RCC management.

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...